UPDATED: Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall
of 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL due to Defective Crimp of the Vial Company Contact: Meredith Teseniar […]
Product News
Voluntary Recall of Sodium Bicarbonate Injection
Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of
8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL, Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL, and ELCYS (cysteine hydrochloride Injection), USP 500 mg/10 mL due to the Presence of Particulate Matter
Voluntary Recall of Sodium Bicarbonate Due to Packaging
Exela Pharma Sciences, LLC Expands and Issues Voluntary Nationwide Recall of Sodium Bicarbonate Injection
Exela Announces Sodium Bicarbonate Injection Partnership
Lenoir, NC September 11, 2019 – Exela Pharma Sciences is pleased to announce the launch of Sodium Bicarbonate Injection, USP. Exela received approval of its ANDA for Sodium Bicarbonate Injection in May for four separate presentations.
Exela Launches ELCYS™ Only FDA Approved Cysteine Hydrochloride Injection
Lenoir, NC May 31, 2019 – Exela Pharma Sciences is pleased to announce the approval and immediate launch of ELCYS™ (cysteine hydrochloride injection), USP, the only FDA Approved cysteine hydrochloride injection on the market in the United States.